comparing the effect of a preprocedural loading dose of atorvastatin vs. rosuvastatin on the prevalence of no-reflow and low timi flow in patients with st-elevation myocardial infarction undergoing primary percutaneous intervention

Background: as a promising revascularization therapy, percutaneous coronary intervention (pci) is widely used in patients with coronary artery disease. no-reflow and low thrombolysis in myocardial infarction (timi) flow are two adverse periprocedural events. objectives: this study aimed to compare the effectiveness of atorvastatin and rosuvastatin in reducing the no-reflow phenomenon in patients undergoing primary pci. methods: following a randomized control design, 280 eligible patients with no history of mi or ischemic heart disease (ihd) with st-elevation myocardial infarction (stemi) who were candidates for coronary angioplasty underwent angioplasty from may 2020 to december 2020. results: our results showed that timi flow iii was significantly higher in the rosuvastatin group, while the no-reflow was not seen in this group (p < 0.001). also, st resolution after 90 minutes of pci was significantly better in the rosuvastatin group. conclusions: this study demonstrated that using a loading dose of rosuvastatin could reduce the no-reflow phenomenon in patients undergoing primary pci.